For a better experience of our website please update you web browser from IE11 to Microsoft Edge or an alternative modern browser such as Google Chrome. Thank you.
Your partner in science for end-to-end CRDMO solutions
The highly-experienced structural biology team at Jubilant Biosys supports structure-based drug discovery from gene to protein co-crystal structures with small-molecule compounds at high resolution using x-ray crystallography.
Jubilant Biosys provides protein expression and protein purification services in three efficient expression systems. Our service comes with a full package – from construct design, gene cloning and expression, custom protein production, protein characterization to crystal hit screening and optimization, x-ray diffraction data collection and structure solving. We also provide recombinant proteins and cells expressing target proteins for functional assays.
The structural biology team provides the following functional services that help to accelerate small-molecule drug discovery and have a track record serving more than 20 pharmaceutical/biotech companies worldwide.
Jubilant Biosys offers high-quality proteins for enzymatic assays, high throughput screening, biophysical and structural studies. The team has worked on ~80 protein targets and delivered more than 300 proteins. Recombinant protein services helped customers’ need for high throughput screening activity.
The Jubilant Biosys team has demonstrated its strength in protein engineering to suit the needs of crystallization by designing multiple constructs for a given gene-to-structure project and worked on ~40 different protein targets and delivered more than 250 co-crystal structures (better than 2.5Å resolution). The structural work has been showcased through publications in peer-reviewed international journals (where the Biosys team is co-authored with clients).
Jubilant Biosys has the experience in handling target genes that encompass kinases, carboxylases, ion-channels, GPCRs, lipases, etc. in generating stables in different cell backgrounds by using plasmid-mediated or lentiviral mediated transfection.